The Motley Fool compared HeartFlow and NovoCure and concluded that NovoCure is the better buy for long-term investors in 2026. HeartFlow, which uses AI for non-invasive coronary artery disease diagnosis, reported fiscal 2025 revenue of approximately $176 million, a 40% increase, but a net loss of $116.8 million. NovoCure, which develops Tumor Treating Fields therapy for cancer, generated about $655.4 million in revenue, up 8.3%, with a net loss of nearly $136.2 million. NovoCure's projected fiscal 2026 revenue of $704 million and lower price-to-sales ratio of 2.5x compared to HeartFlow's 15.5x make it the preferred choice despite both companies not expected to generate positive free cash flow until 2028.
Novocure LtdArticle concludes NovoCure is the better buy due to lower price-to-sales ratio and higher projected revenue, implying favorable valuation.
Heartflow, Inc. Common StockArticle compares HeartFlow to NovoCure, noting HeartFlow's higher price-to-sales ratio and net loss, but does not provide a clear positive or negative event for HeartFlow.